Table 1. Agents in phase I clinical trials for AD treatments.
Name |
Company |
Mechanism of action or target |
Reference |
AAD-2004 |
GNT Pharma |
Cytokines inhibitor |
159 |
ACI-24 |
AC Immune’s Supramolecular Technology |
Anti beta-amyloid |
50 |
ACI-35 |
ACImmune |
Tau aggregation |
82, 83 |
ALZ-801 |
Alzheon |
Preventing aggregation of beta-amyloid |
76 |
ARC-031 |
Archer Pharmaceuticals |
Calcium channel blocker, antioxidant |
111 |
ASP-3662 |
Astellas Pharma |
Inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1 |
135 |
AUS-131 |
Ausio Pharmaceuticals |
Nonhormonal selective estrogen receptor beta (ER beta) agonist |
115 |
AVN-322 |
Avineuro |
5-HT6 receptor antagonist |
95 |
Basmisanil (RG-1662) |
Roche |
GABA(A) receptor agonist |
118 |
BI-1181181 |
Boehringer Inhelheim |
BACE-1 inhibitor |
66 |
Bisnorcymserine |
QR Pharma |
Selective Inhibitor of butyrylcholinesterase (BuChE) |
130, 131 |
BMS-932481 |
Bristol-Myers Squibb |
BACE-1 inhibitor |
68 |
BMS-986168 |
Bristol-Myers Squibb |
Tau aggregation |
84 |
BPN14770 |
Tetra Discovery Partners |
Phosphodiesterase Inhibitor |
140 |
Copaxone |
Cedar-Sinai Medical Center |
Immunomodulator |
153 |
Exebryl-1 |
ProteoTech |
Modulator of β- and α-secretase activity |
78 |
FGL-2 |
Enkam |
Stimulates the secretion of nerve growth factor |
150 |
GC-021109 |
GliaCure |
Inducer of phagocytosis |
160 |
GSK-2647544 |
GSK |
Inhibitor of phospholipase A2 |
138 |
Huperzine A, Cerebra |
NutriHerb |
NMDAR antagonist, signal transduction modulator, AChEI |
203 |
KHK-6640 |
Kyowa Hakko Kirin |
Anti beta-amyloid |
59 |
Lu-AF-20513 |
Lundbeck |
Anti beta-amyloid |
60 |
MEDI-1814 |
AstraZeneca |
Anti beta-amyloid |
58 |
Memogain |
Neurodyn Life Sciences |
Non-selective inhibitor of butyryl- and acetylcholinesterases |
132 |
NsG-0202 |
NsGene |
Stimulates secretion of nerve growth factor |
152 |
PQ-912 |
Probiodrug AG |
Glutaminyl cyclase inhibitor |
144 |
RG-7345 |
Genetech, Hoffmann-La Roche |
Tau aggregation |
80 |
RP-5063 |
Reviva Pharma |
Multitarget |
96 |
SAN-61 |
Diamedica Company |
Stimulates proliferation of neural stem cells acting simultaneously on amyloid plaques and neurofibrillary aggregates |
77 |
SAR-228810 |
Sanofi Company |
Anti beta-amyloid |
57 |
SUVN-G3031 |
Suven Life Sciences |
H3R antagonist |
114 |
Telmisartan |
Astellas Pharma |
PPARalpha agonist, signal transduction modulator, PPARgamma modulator |
172, 173 |
TPI-287 |
Cortice Biosciences |
Tau aggregation |
90 |
TTP-4000 |
Trans Tech Pharma |
Recombinant proteins affecting beta-amyloid |
61 |